Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

1. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.Haematologica · 2011
   Trial
2. Siglec15 in blood system diseases: from bench to bedside.Frontiers in immunology · 2024
   Review
3. The intriguing roles of Siglec family members in the tumor microenvironment.Biomarker research · 2022
   Review
4. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.Cancer immunology, immunotherapy : CII · 2021
   Article
5. High-Dimensional Analysis of Single-Cell Flow Cytometry Data Predicts Relapse in Childhood Acute Lymphoblastic Leukaemia.Cancers · 2020
   Article
6. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.International journal of molecular sciences · 2020
   Review
7. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cellsHaematologica · 2017
   Article
8. Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.Oncotarget · 2016
   Article
9. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.Pharmaceutical research · 2015
   Review
10. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.Leukemia · 2014
    Article
11. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Drugs · 2013
    Review
12. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.Haematologica · 2010
    Article
13. Specific induction of CD33 expression by E2A-HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor.Leukemia · 2010
    Article
14. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens.BMC cancer · 2005
    Article
15. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.mAbs
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as